TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2.


Journal

Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698

Informations de publication

Date de publication:
10 07 2023
Historique:
received: 17 03 2023
accepted: 25 05 2023
medline: 12 7 2023
pubmed: 11 7 2023
entrez: 10 7 2023
Statut: epublish

Résumé

The reintegration of excised signal joints resulting from human V(D)J recombination was described as a potent source of genomic instability in human lymphoid cancers. However, such molecular events have not been recurrently reported in clinical patient lymphoma/leukemia samples. Using a specifically designed NGS-capture pipeline, we here demonstrated the reintegration of T-cell receptor excision circles (TRECs) in 20/1533 (1.3%) patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Remarkably, the reintegration of TREC recurrently targeted the tumor suppressor gene, ZFP36L2, in 17/20 samples. Thus, our data identified a new and hardly detectable mechanism of gene deregulation in lymphoid cancers providing new insights in human oncogenesis.

Identifiants

pubmed: 37430263
doi: 10.1186/s12943-023-01794-y
pii: 10.1186/s12943-023-01794-y
pmc: PMC10332067
doi:

Substances chimiques

ZFP36L2 protein, human 0
Transcription Factors 0

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108

Informations de copyright

© 2023. The Author(s).

Références

Blood. 2012 Oct 18;120(16):3298-309
pubmed: 22948044
J Exp Med. 2002 Jan 7;195(1):85-98
pubmed: 11781368
Nature. 2022 Nov;611(7934):105-114
pubmed: 36198798
PLoS Genet. 2022 Oct 13;18(10):e1010421
pubmed: 36228010
Front Immunol. 2019 Jul 04;10:1572
pubmed: 31333681
J Exp Med. 2017 Mar 6;214(3):815-831
pubmed: 28179379
Genes Chromosomes Cancer. 2012 Jun;51(6):525-35
pubmed: 22334400
Haematologica. 2013 Aug;98(8):1173-84
pubmed: 23904235
Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):373-378
pubmed: 29279377
J Exp Med. 2007 Oct 1;204(10):2293-303
pubmed: 17785508
Cancers (Basel). 2020 Jun 11;12(6):
pubmed: 32545247
DNA Repair (Amst). 2006 Sep 8;5(9-10):1234-45
pubmed: 16793349
Nat Immunol. 2010 Aug;11(8):717-24
pubmed: 20622884
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
EMBO J. 2003 Mar 17;22(6):1381-8
pubmed: 12628930
Annu Rev Immunol. 2006;24:541-70
pubmed: 16551259
Adv Immunol. 2018;139:93-135
pubmed: 30249335
PLoS Biol. 2007 Mar;5(3):e43
pubmed: 17298184

Auteurs

Estelle Balducci (E)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Thomas Steimlé (T)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.
TAGC, UMR 1090, Aix-Marseille University, INSERM, Marseille, France.

Charlotte Smith (C)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Patrick Villarese (P)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Mélanie Feroul (M)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Dominique Payet-Bornet (D)

Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France.

Sophie Kaltenbach (S)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Lucile Couronné (L)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Ludovic Lhermitte (L)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Aurore Touzart (A)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Marie-Emilie Dourthe (ME)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Mathieu Simonin (M)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

André Baruchel (A)

Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
Institut Universitaire d'Hématologie, EA-3518, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.

Hervé Dombret (H)

Université Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, Assistance Publique-Hôpitaux de Paris, University Hospital Saint-Louis, 75010, Paris, France.

Norbert Ifrah (N)

PRES LUNAM, CHU Angers Service Des Maladies du Sang, INSERM U 892, 49933, Angers, France.

Nicolas Boissel (N)

Université Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, Assistance Publique-Hôpitaux de Paris, University Hospital Saint-Louis, 75010, Paris, France.

Bertrand Nadel (B)

Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France.

Elizabeth Macintyre (E)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France.

Agata Cieslak (A)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. agata.cieslak@aphp.fr.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France. agata.cieslak@aphp.fr.

Vahid Asnafi (V)

Laboratory of Onco-Hematology, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. vahid.asnafi@aphp.fr.
Université Paris Cité, CNRS, INSERM U1151, Institut Necker Enfants Malades (INEM), Paris, France. vahid.asnafi@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH